Neuroendocrine tumors of the gastro-entero-pancreatic system
Open Access
- 1 January 2008
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (35), 5377-5384
- https://doi.org/10.3748/wjg.14.5377
Abstract
Gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, although their prevalence has increased substantially over the past three decades. Moreover, there has been an increased clinical recognition and characterization of these neoplasms. They show extremely variable biological behavior and clinical course. Most NETs have endocrine function and secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome; however, many are clinically silent until late presentation with mass effects. Investigation and management should be individualized for each patient, taking into account the likely natural history of the tumor and general health of the patient. Management strategies include surgery for cure or palliation, and a variety of other cytoreductive techniques, and medical treatment including chemotherapy, and biotherapy to control symptoms due to hormone release and tumor growth, with somatostatin analogues (SSAs) and alpha-interferon. New biological agents and somatostatin-tagged radionuclides are under investigation. Advances in the therapy and development of centers of excellence which coordinate multicenter studies, are needed to improve diagnosis, treatment and therefore survival of patients with GEP NETs.Keywords
This publication has 64 references indexed in Scilit:
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Neuroendocrine tumours (carcinoids) of the appendixBest Practice & Research Clinical Gastroenterology, 2005
- Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatmentBest Practice & Research Clinical Gastroenterology, 2005
- Neuroendocrine Hepatic MetastasesAnnals of Surgery, 2005
- The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?European Journal of Cancer, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Carcinoid Tumor of the Appendix: Treatment and PrognosisThe New England Journal of Medicine, 1987
- Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid SyndromeThe New England Journal of Medicine, 1983